• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调节性 T 细胞的治疗潜力:挑战与机遇。

The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities.

机构信息

Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Research & Development Department, Aryogen Pharmed, Karaj, Iran.

出版信息

Front Immunol. 2021 Jan 15;11:585819. doi: 10.3389/fimmu.2020.585819. eCollection 2020.

DOI:10.3389/fimmu.2020.585819
PMID:33519807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7844143/
Abstract

Regulatory T cells (Tregs) are an immunosuppressive subgroup of CD4 T cells which are identified by the expression of forkhead box protein P3 (Foxp3). The modulation capacity of these immune cells holds an important role in both transplantation and the development of autoimmune diseases. These cells are the main mediators of self-tolerance and are essential for avoiding excessive immune reactions. Tregs play a key role in the induction of peripheral tolerance that can prevent autoimmunity, by protecting self-reactive lymphocytes from the immune reaction. In contrast to autoimmune responses, tumor cells exploit Tregs in order to prevent immune cell recognition and anti-tumor immune response during the carcinogenesis process. Recently, numerous studies have focused on unraveling the biological functions and principles of Tregs and their primary suppressive mechanisms. Due to the promising and outstanding results, Tregs have been widely investigated as an alternative tool in preventing graft rejection and treating autoimmune diseases. On the other hand, targeting Tregs for the purpose of improving cancer immunotherapy is being intensively evaluated as a desirable and effective method. The purpose of this review is to point out the characteristic function and therapeutic potential of Tregs in regulatory immune mechanisms in transplantation tolerance, autoimmune diseases, cancer therapy, and also to discuss that how the manipulation of these mechanisms may increase the therapeutic options.

摘要

调节性 T 细胞(Tregs)是 CD4 T 细胞中的一个免疫抑制亚群,其特征是表达叉头框蛋白 P3(Foxp3)。这些免疫细胞的调节能力在移植和自身免疫性疾病的发展中起着重要作用。这些细胞是自身耐受的主要介质,对于避免过度的免疫反应至关重要。Tregs 通过保护自身反应性淋巴细胞免受免疫反应,在诱导外周耐受中发挥关键作用,从而防止自身免疫。与自身免疫反应相反,肿瘤细胞在癌变过程中利用 Tregs 来防止免疫细胞识别和抗肿瘤免疫反应。最近,许多研究集中在揭示 Tregs 的生物学功能和原理及其主要抑制机制上。由于有希望和突出的结果,Tregs 已被广泛研究作为预防移植物排斥和治疗自身免疫性疾病的替代工具。另一方面,为了改善癌症免疫治疗而针对 Tregs 的研究也正在被深入评估,作为一种理想且有效的方法。本文旨在指出 Tregs 在移植耐受、自身免疫性疾病、癌症治疗中的调节免疫机制中的特征功能和治疗潜力,并讨论这些机制的操纵如何增加治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/13d42b60cf1f/fimmu-11-585819-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/fb05b797c4c2/fimmu-11-585819-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/57d16cfc871a/fimmu-11-585819-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/103d8bb4f760/fimmu-11-585819-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/4f32cb037237/fimmu-11-585819-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/58acaa1e6db9/fimmu-11-585819-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/13d42b60cf1f/fimmu-11-585819-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/fb05b797c4c2/fimmu-11-585819-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/57d16cfc871a/fimmu-11-585819-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/103d8bb4f760/fimmu-11-585819-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/4f32cb037237/fimmu-11-585819-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/58acaa1e6db9/fimmu-11-585819-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300f/7844143/13d42b60cf1f/fimmu-11-585819-g006.jpg

相似文献

1
The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities.调节性 T 细胞的治疗潜力:挑战与机遇。
Front Immunol. 2021 Jan 15;11:585819. doi: 10.3389/fimmu.2020.585819. eCollection 2020.
2
Foxp3, Regulatory T Cell, and Autoimmune Diseases.叉头框蛋白3、调节性T细胞与自身免疫性疾病
Inflammation. 2017 Feb;40(1):328-339. doi: 10.1007/s10753-016-0470-8.
3
Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity.调节性 T 细胞治疗在移植和自身免疫中的过去、现在和未来。
Front Immunol. 2019 Jan 31;10:43. doi: 10.3389/fimmu.2019.00043. eCollection 2019.
4
Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations.调节性 T 细胞:免疫平衡的掌控者和未来治疗创新的源泉。
Front Immunol. 2024 Sep 3;15:1457189. doi: 10.3389/fimmu.2024.1457189. eCollection 2024.
5
Regulatory T cells: a review.调节性T细胞:综述
Natl Med J India. 2012 Nov-Dec;25(6):341-51.
6
FoxP3 T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.FoxP3+ T 调节性细胞在癌症中的作用:预后生物标志物和治疗靶点。
Cancer Lett. 2020 Oct 10;490:174-185. doi: 10.1016/j.canlet.2020.07.022. Epub 2020 Jul 25.
7
Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.通过增强调节性 T 细胞来恢复自身免疫性疾病中的自身耐受性。
Cell Immunol. 2019 May;339:41-49. doi: 10.1016/j.cellimm.2018.09.008. Epub 2018 Sep 29.
8
FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance.FOXP3+ 调节性 T 细胞:从排斥抑制到诱导肾移植耐受。
Transpl Immunol. 2012 Jan;26(1):1-10. doi: 10.1016/j.trim.2011.08.009. Epub 2011 Sep 13.
9
Regulatory T cells in immune-mediated renal disease.免疫介导性肾脏疾病中的调节性T细胞。
Nephrology (Carlton). 2016 Feb;21(2):86-96. doi: 10.1111/nep.12574.
10
Regulatory T cells in kidney disease and transplantation.调节性 T 细胞在肾脏疾病和移植中的作用。
Kidney Int. 2016 Sep;90(3):502-14. doi: 10.1016/j.kint.2016.03.022. Epub 2016 Jun 3.

引用本文的文献

1
Historically Based Perspective on the Immunotherapy of Type 1 Diabetes: Where We Have Been, Where We Are, and Where We May Go.基于历史视角的1型糖尿病免疫治疗:我们的过去、现在与未来。
J Clin Med. 2025 Aug 8;14(16):5621. doi: 10.3390/jcm14165621.
2
Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.改善肝细胞癌免疫治疗:从患者和临床前模型中学习。
Gut Liver. 2025 Apr 3;2(1). doi: 10.1038/s44355-025-00018-y.
3
Induced Treg-Derived Extracellular Vesicles Suppress CD4 T-Cell-Mediated Inflammation and Ameliorate Bone Loss During Periodontitis Partly Through CD73/Adenosine-Dependent Immunomodulatory Mechanisms.

本文引用的文献

1
CAR-Tregs as a Strategy for Inducing Graft Tolerance.嵌合抗原受体调节性T细胞作为诱导移植耐受的一种策略。
Curr Transplant Rep. 2020 Sep;7(3):205-214. doi: 10.1007/s40472-020-00285-z. Epub 2020 Jul 4.
2
Treg Enhancing Therapies to Treat Autoimmune Diseases.调节性 T 细胞增强疗法治疗自身免疫性疾病。
Int J Mol Sci. 2020 Sep 23;21(19):7015. doi: 10.3390/ijms21197015.
3
Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.鉴定、选择和扩增非基因修饰的同种抗原反应性 Tregs 用于临床治疗用途。
诱导性调节性T细胞衍生的细胞外囊泡可抑制CD4 T细胞介导的炎症,并部分通过CD73/腺苷依赖性免疫调节机制改善牙周炎期间的骨质流失。
J Extracell Vesicles. 2025 Jul;14(7):e70118. doi: 10.1002/jev2.70118.
4
The role of T-helper and T regulatory cells in driving neutrophilic and eosinophilic inflammation in bronchiectasis.辅助性T细胞和调节性T细胞在支气管扩张症中引发嗜中性粒细胞性和嗜酸性粒细胞性炎症方面的作用。
Front Immunol. 2025 Jun 16;16:1598257. doi: 10.3389/fimmu.2025.1598257. eCollection 2025.
5
Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy.克服胶质母细胞瘤中的障碍:嵌合抗原受体T细胞免疫疗法的潜力。
Theranostics. 2025 Jun 12;15(14):7090-7126. doi: 10.7150/thno.114257. eCollection 2025.
6
Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets.胰腺癌中的免疫抑制性肿瘤微环境:机制与治疗靶点
Front Immunol. 2025 May 15;16:1582305. doi: 10.3389/fimmu.2025.1582305. eCollection 2025.
7
The role of the tumour microenvironment in lung cancer and its therapeutic implications.肿瘤微环境在肺癌中的作用及其治疗意义。
Med Oncol. 2025 May 23;42(6):219. doi: 10.1007/s12032-025-02765-7.
8
Regulatory T Cells Kinetics in Immune Reconstitution Inflammatory Syndrome in HIV-Tuberculosis Co-Infected Individuals.HIV-结核合并感染个体免疫重建炎症综合征中调节性T细胞的动力学
J Mol Clin Med. 2025;8(1). doi: 10.31083/JMCM25012. Epub 2025 Feb 5.
9
Rac1 overexpression promotes Treg-derived cytokines to mediate choroidal neovascularization in wet age-related macular degeneration.Rac1过表达促进调节性T细胞衍生细胞因子介导湿性年龄相关性黄斑变性中的脉络膜新生血管形成。
Braz J Med Biol Res. 2025 Mar 3;58:e14187. doi: 10.1590/1414-431X2024e14187. eCollection 2025.
10
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.调控性 T 细胞选择性白介素-2 受体激动剂 rezpegaldesleukin 治疗炎症性皮肤病:两项随机、双盲、安慰剂对照的 1b 期试验。
Nat Commun. 2024 Oct 25;15(1):9230. doi: 10.1038/s41467-024-53384-1.
Cell Immunol. 2020 Nov;357:104214. doi: 10.1016/j.cellimm.2020.104214. Epub 2020 Sep 9.
4
PD-1 T cells: a foe in cancer immunotherapy?PD-1 细胞:癌症免疫疗法的敌人?
Nat Immunol. 2020 Nov;21(11):1311-1312. doi: 10.1038/s41590-020-0801-7.
5
Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors.CC 趋化因子受体 8 蛋白在胃肠道间质瘤中的表达及其临床预后意义。
World J Gastroenterol. 2020 Aug 21;26(31):4656-4668. doi: 10.3748/wjg.v26.i31.4656.
6
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.效应 T 细胞和调节性 T 细胞之间的 PD-1 表达平衡可预测 PD-1 阻断疗法的临床疗效。
Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31.
7
New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression.基于新型调节性 T 细胞的自身免疫性疾病治疗方法:朝着抗原特异性免疫抑制的方向发展。
Curr Opin Immunol. 2020 Dec;67:36-41. doi: 10.1016/j.coi.2020.07.004. Epub 2020 Aug 19.
8
New emerging targets in cancer immunotherapy: the role of GITR.癌症免疫治疗中的新新兴靶点:GITR 的作用。
ESMO Open. 2020 Aug;4(Suppl 3):e000738. doi: 10.1136/esmoopen-2020-000738.
9
Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.靶向调节性 T 细胞改善癌症治疗:挑战与展望。
Cancer Rep (Hoboken). 2018 Jun;1(1):e21105. doi: 10.1002/cnr2.1105. Epub 2018 May 15.
10
Inducers, Attractors and Modulators of CD4 Treg Cells in Non-Small-Cell Lung Cancer.非小细胞肺癌中 CD4+Treg 细胞的诱导物、吸引物和调节剂。
Front Immunol. 2020 Apr 28;11:676. doi: 10.3389/fimmu.2020.00676. eCollection 2020.